Protecting the Gut Microbiome

Synthetic Biologics is pioneering cutting-edge microbiome science designed to preserve the microbiome to protect and restore the health of patients.

Our two lead programs in late-stage clinical development are SYN-004 (ribaxamase), deigned to protect the natural gut microbiome to prevent antibiotic-mediated primary C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR) and SYN-010, designed to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

View SYN-004 (ribaxamase) View SYN-010

About Synthetic Biologics

We are a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.

Learn More

Leadership

Our experienced management team has an extensive clinical and commercial track record.

Latest News

Sep 12, 2017 • 7:00am EDT

Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage c

View all news

Investor Relations

NYSE AmericanSymbol SYN
Price
Change
Volume
Day Low/High
52 Week Low/High